Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 29, 2015 10:24 AM ET

Biotechnology

Company Overview of Enanta Pharmaceuticals, Inc.

Company Overview

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the infectious disease field in the United States. Its product portfolio includes ABT-450, a protease inhibitor that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV); ABT-493, a next-generation protease inhibitor for HCV infection; EDP-239, an NS5A inhibitor for HCV infection; Cyclophilin inhibitor, which are in preclinical development stage for HCV infection treatment; and Nucleotide Polymerase inhibitor program for HCV infection. The company also develops Bicyclolide antibiotic products focuses on mechanisms gram-positive pathogens, including bacteria resistant...

500 Arsenal Street

Watertown, MA 02472

United States

Founded in 1995

52 Employees

Phone:

617-607-0800

Fax:

617-607-0530

Key Executives for Enanta Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 59
Total Annual Compensation: $751.8K
Chief Financial Officer and Senior Vice President of Finance & Administration
Age: 60
Total Annual Compensation: $440.3K
Chief Scientific Officer and Senior Vice President of Research & Development
Age: 63
Total Annual Compensation: $514.1K
Compensation as of Fiscal Year 2014.

Enanta Pharmaceuticals, Inc. Key Developments

Enanta Pharmaceuticals, Inc. Announces U.S. Regulatory Approval of TECHNIVIE™ Tablets

Enanta Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved AbbVie’s TECHNIVIE™ (ombitasvir, paritaprevir and ritonavir) tablets in combination with ribavirin (RBV) for the treatment of non-cirrhotic adults with genotype 4 (GT4) chronic hepatitis C virus (HCV) infection.

Enanta Pharmaceuticals, Inc. Announces the Appointment of Nathalie Adda as Chief Medical Officer

Enanta Pharmaceuticals, Inc. announced the appointment of Nathalie Adda, M.D., as Senior Vice President and Chief Medical Officer, responsible for clinical and regulatory affairs. Dr. Adda is a specialist in infectious disease and has more than 15 years of experience in the pharmaceutical industry in all phases of global clinical research and development and commercialization. Most recently, Dr. Adda was Chief Medical Officer, VP Clinical Development, Medical and Regulatory Affairs at Transgene SA, where she led the Oncology and Infectious Disease programs since 2012.

Enanta Pharmaceuticals, Inc. Announces New Data from AbbVie’s Phase 3 Gift-I Study

Enanta Pharmaceuticals, Inc. announced that new data from AbbVie’s phase 3 GIFT-I study, its investigational, all-oral, interferon (IFN)- and ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir, was presented at the Annual Meeting of the Japan Society of Hepatology in Kumamoto, Japan. GIFT-I evaluated genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected Japanese patients, with and without cirrhosis, who were either treatment-naïve or Interferon (with or without RBV) treatment-experienced. The primary endpoint was achieved, demonstrating 95% (n=106/112) SVR12 in a sub-group of treatment-naïve, non-cirrhotic, adult GT1b HCV infected Japanese patients who were eligible for therapy with IFN and had a high viral load.1 In study results related to the secondary endpoint, GT1b HCV patients with compensated cirrhosis achieved 91% (n=38/42) SVR12. In an additional intent-to-treat (ITT) analysis, SVR12 was achieved in 98% (n=104/106) of the GT1b HCV infected patients without cirrhosis (Arm B) who were randomized to initially receive double-blind placebo for 12 weeks, followed by open-label treatment with ombitasvir/paritaprevir/ritonavir. The ITT population included every patient that was randomized to placebo and received at least one dose of active, open-label study drug. Across all study arms, three patients (n=3/363) discontinued treatment due to adverse events. The most commonly reported adverse events (>5% in any arm) were nasopharyngitis, headache, peripheral edema, nausea, pyrexia and decreased platelet count.

Similar Private Companies By Industry

Company Name Region
Sharklet Technologies, Inc. United States
Biomerix Corporation United States
Cooperative Resources International, Inc. United States
AxioMx, Inc. United States
Avantome, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Enanta Pharmaceuticals, Inc., please visit www.enanta.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.